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Although the Breslow measurement of tumor thick-
ness of melanoma is the most significant predictor of 
survival, the biologic behavior of thick lesions re-
mains unpredictable. MIB-1, a monoclonal antibody 
to a Ki-67 epitope, recognizes all proliferating cells. 
Unlike Ki-67 antibody, which requires frozen tissue, 
Mffi-1 can be used on formalin-:-fixed tissue. Prolifer-
ation, measured by MIB-1 expression and mitotic 
index, was assessed as a prognostic factor in a group 
of patients with clinical stage I thick cutaneous mel-
anoma (tumor thickness 4 mm or greater), for which 
predicted survival is low. From a melanoma data 
base, 97 patients with this type of melanoma were 
identified. Of these, 64 had lesional tissue available 
for study. The median follow-up time was 3.8 years 
(range 0.42-13.6 years). The percentage of MIB-1 
reactivity was scored as low at less than 10% (n = 33), 
0 ver the past 30 years, the incidence and mortality rates of melanoma have increased dramatically. At the sam e time, our knowledge of the biologic behavior of melanoma has been furthered by the studies of Clark et a/ (1,2]. Prognosis is di.rectly 
related to the depth of invasion in the dermis [2,3], and the single 
most important predictor of survival is the thickness of the mela-
noma m easured from the granular layer of the epidermis to the 
deepest portion of the tumor [3]. Although other pathologic 
features such as the nature of the lymphocytic infiltrate, ulceration , 
regression, mitotic rate, and vascular invasion may add prognostic 
infom1ation (4-6] , m elanoma remains an unpredictable disease. 
Deaths have been reporte d in patients with thin melanomas of less 
than 0.76 mm, a vertical measurement that was originally thought 
to be associated with a virtual cure [7]. Even thick melanomas have a 
variable prognosis. At least SO'!Io to 75% of patients with melanomas 
4 mm thick or greater will die of their disease within a few years; 
the re maining 25% to 50% of patients survive for unknown reasons 
(7]. Other factors may be important in determining the clinical 
outcome of this challenging disease. 
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Abbreviation: PCNA, proliferating cell nuclear antigen. 
intermediate at 10% to 20% (n = 17), and high at 
greater than 20% (n = 14). Melanomas with high 
MIB-1 reactivity were associated with significantly 
poorer cause-specific survival compared with tumors 
with intermediate (p < 0.0001) or low MIB-1 reactiv-
ity (p = 0.0025). Multivariate analysis demonstrated 
that Mffi-1 reactivity was a significant independent 
prognostic factor related to cause-specific survival 
(p = 0.0002) and was more sensitive than tumor 
thickness or mitotic index in this select group of 
high-risk patients. Identification of individuals 
with stage I thick cutaneous melanoma who are at 
risk of recurrent disease may improve patient man- 1 
agement as new therapeutic modalities become 
available. Key IVOYds: pvolifevatiolllantibodylimnumollis· 
tochemistvy.] Invest Del'matol 105:22-26, 1995 
The mitotic rate or index, identified as an independent prognos-
tic factor in melanoma by Clark ct a/ [4], is calculated on hematox-
ylin and eosin-stained sections and expressed as the number of 
mitotic figures per 10 high-power fi e lds or per l.O-mm2 area (8] . 
Although this is easily perfonned, tissue section tluckness and 
subjectivity may confound the determination of the mitotic rate or 
index. Furthermore, mitoses represent only a small portion of the 
growth cycle, whereas a proliferation antigen such as Ki-67 is 
expressed throughout the growth phase of the cell cycle (G .1, M, 
G2 , and S, though not in G 0) [9, 10]. The proliferative rate measured 
with the Ki-67 antibody has been suggested to be valuable in 
predicting the prognosis of melanoma [11, 12]. lmmunolustochem-
istry with the Ki-67 antibody can be performed only on frozen 
tissue, however, and studies using this antibody thus have been 
limited by the availability of fresh tissue and by a relatively short 
follow-up period [13]. Proliferating cell nuclear antigen (PCNA) is 
another proliferation marker that has been used in assessing tumor 
aggressiveness or prognosis of melanocytic neoplasms (14-17]. 
A lthough PCNA has the advantage of bei.ng detected in formalin-
fixed tissue, immunohistochemical determination of proliferation 
using this antibody may not accurately reA.ect the proportion of cells 
in the growth cycle, for several reasons [13,18] . The number of 
PCNA immunoreactive nuclei may be altered by .difFerent tissue 
processing tecluuques [19), and the half-life of the PCNA antigen 
exceeds the cell cycle time (20]. Consequently, proliferation rates 
based on PCNA immunolustochem.istry may be an inaccurate 
estimate of the number of proliferating cells. Recently, a new 
0022-202X/95/S09.50 • SSD10022-202X(95)00164-G • Copyright 1995 by The Society for Investigative Dermatology, Inc. 
22 
VOL. lOS , NO. 1 JULY 1995 
murine monoclonal antibody, Mlli-1 , bas been d e veloped u sin g 
recombinant portions of the Ki-67 nucl ear antigen as an immuno-
gen [21). MIB-1 recognizes the K.i-67 nuclear antigen on fom1alin-
£Lxed, paraffin-embedded tissue [22], and thus proliferative studies 
can now be performed on archival tissue. Our pre liminary study of 
MIB-1 expression in primary cutaneous and metastatic melanomas 
showed a progressive increase of Mlli-1 proliferative rates in 
primary tumors with deeper levels of invasion and a marked 
increase in the level of MIB-1 expression in metastatic lesion s.** 
These results are comparable to earli e r K.i-67 immunohistochemical 
studies of m e lanocytic neoplasms that demonstrated increased 
proliferation associated with tumor and tumor aggressiveness 
(11 '12,23-26]. 
In this study, we assessed the proliferative ac tivity of primary 
thick c utaneous m elanomas (tumor thickness 4 mm or greate r) 
using the MrB-1 antibody , comparing the immunohistochemical 
results with the mitotic inde x and re lating both factors to clinical 
outcome . 
MATEIUALS AND METHODS 
Selection of Patients Since 1980, data on patients with cutaneous 
melanoma who are consecutively registered and followed up at the 
Toronto-B:Jyview Regional Cancer Centre have been entered in a Medlog 
data base (M edlog Systems Information Analysis C orporation, I.ncl.ine 
Village, NV). T he data base documents clinical and pathologic factors in 
addition to cljnical outcome. These factors include demographics, site of the 
lesion , family hjstory of melanoma , presence or absence of dysplastic nevi, 
biologic type of melanoma, Clark level of invasion, Breslow vertica l height, 
ulceration, and regression. T he data base was searched for all patients with 
clinical stage I cutaneous melanomas measuring 4 mm or greater in vertical 
tluckness. 
Pathology and Immunohistochemical Methods The hemato>..)'lin 
and eosin-stained tissue sections of the primary tumors were reviewed after 
the patient's initial visit. Breslow measurement of tumor tlllckness , C lark 
level, and tumor type were coJtlirmed, and other pathologic features such as 
ulceration and regressio•! were recorded. 
The pru·affin blocks of the primary tumors were re tri eved from the 
referring laboratories. One or two representative sections of the deepest 
areas of each tumor were stained with hematoxylin and eosin. T he mitotic 
index was calculated for each tumor using the mctl10d of Schmocckel and 
Brann-Falco [8). Areas oflugher mitotic rates were selected by screening at 
low magnification; tl1e number of mitotic figures was counted in 10 
high-power fields (at least 1.5 mm 2) at 400 X mag1ufication and expressed 
as mitotic figurcs/mm 2 • 
. An adjacent section 4 f.Lm duck was used for immunolustochemica) study 
with the murine monoclonal antibody M.ID-1 {lmmunotech, Boston, MA) 
by the biotin streptavidjn in.ununoperoxidase teclutique. Briefly, after 
blocking of endogenous peroxidase with 3'% hydrogen peroxide, the 
paraffin sections were processed in a 750-W household m.i crowave oven at 
maximum power for 5 min and then at 50% power for 3 min , three times, 
to enhance antigen detection. T he primary antibody, diluted 1:50 in 0.1% 
gelatin , was applied for 2 h. The multilink antibody (Dakopatts, Glostrup, 
D enmark) was applied for 10 min and was fo llowed by the streptavidin 
complex. For visualization of the Mffi-1 antibody, the slides were devel-
oped in 0.3% 3' amino 9' ethylcarbazole; Harris hemato>..)'lin was used as a 
counterstain. Tonsils were used as control tissue, and stainjng of basal 
keratinocytes of tl1e epidermis served as an internal control. 
Assessment of MIB-1 Immunoreactivity The overall pattem of 
Mffi-1. staining of a tumor was categorized as either diffuse if immunore-
active nuclei were evenly rustrjbuted tluoughout the le.,ion, 01· foca l if 
M.ID-1-positive nuclei were observed in aggregates. At least four fields of 
100 tumor cells each (total at least 400 tumor nuclei) per slide were co tmted 
at 400 X magnjfication. T he number of MIB-1-immunoreactive nucle i in 
each field was determined and subsequently expressed as a percentage of tl1e 
total number of tumor nuclei counted. A mean percentage of MlB-1.-
immunoreactive tumor nuclei was calculated for each lesion. The MIB-1 
percen tages were scored as low (less than 1 0%), intermediate (1 0% to 20%), 
or lugh (greater than 20%). Mffi-1. proliferative activity was assessed 
wjtl10ut lmowledge of the clinical outcome. 
• • From L, Kahn 1:-lJ: MIJ3-·I proliferative actlVlty in primary and 
metastatic melanomas (abstr). Brj Demrarol ·t 29 (suppl 42):18, 1993. 
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Table I. Clinicopathologic Features of Patients With 
Clinical Stage I Thick Cutaneous Melanomas (Tumor 
Thickness 4.00 mm or Greater) 
Feature 
Sex (male:female) 
Age at ruagnosis (years) 
Mean 
Range 
Site 
Face 
Scalp 
Neck 
Trunk 
Am1 
Leg 
Foot 
Histology 
Superficial sprcadi11g 
Nodular 
Lentigo maligna melanoma 
Desmoplastic 
Acral lentiginous 
Not classifiable 
Tumor thjckness (nun) 
M ean 
Median 
Range 
Follow-up time (years) 
Median 
R ange 
O utconle1' 
ANED 
AWD 
DNED 
DWD 
LTFU 
Number 
(N = 64) 
46:18 
54.0 
18.6- 87.5 
8 
4 
1 
29 
4 
13 
5 
20 
31 
1 
3 
2 
7 
5.76 
5.00 
4.00 -1 5.00 
3.8 
0.42-1 3.6 
23 
1 
6 
30 
4 
"AN ED. ali ve v.rith no evidence of disease: A WD, alive with disease: DNEO. dead 
with no evidence of disease; DWD. dead w ith disease: LTFU. lost to follow-up. 
Statistics Statistical analyses were performed \vith the Medlog statistical 
software program. Comparisons of continuous data were made by the 
Student t test and of categori c data by the ;of test. Survival curves were 
constructed by the Kaplan-Meier mctl10d and compared by the MaJltel-
Haenszel log-rank test. Multivariate analysis of the association of potential 
prognostic facto rs was assessed by Cox regression analysis. To detem1ine 
the independent efFect of MIU-1 reactivi ty, we included in the multivariate 
analysis all factors that have been dcsc,;bed as predictive of outcome in 
cutaneous melanoma. These prog11ostic t:~cto rs included: sex, site of the 
primary lesion (both site and BANS (upper back, upper postecior arm, 
posterior neck , and scalp region [27))) . age at diagnosis, lusto logic subtype, 
Breslow thjckness, C lark level, tumor regression, ulceration, ru1d prolifer-
ative activity. Proliferative activity included mitotic index, percentage of 
MJB-1 immunoreactiv-ity, and pattern ofMU3-·I struning. Values ofp < 0.05 
were considered statistically signifi cant. 
RESULTS 
Of th e 1287 patie nts in the melanoma d ata base, 97 were classified 
as having clinical stage I disease w ith a pt·imary lesion m easuring 4 
mm or greater in vertical thickness. Adequate tissue was availabl e 
for only 64 patients b ecause some cases had been diagnosed more 
than 10 years before our study, and referring laboratories h ad 
discarded the blocks. Comparison of the 33 cases in which no tissue 
was avail able and the 64 cases include d in the study revealed no 
significant diffe rences in tem1s of age at diagnosis, male to fema.le 
ratio , site of primary lesion , Breslow thickness, Clark level , Justo-
logie type of m elanoma , prese n ce of ulceration and regression, o r 
last cli.Jucal status. Likewise, there was no significant diffe ren ce 
observ e d for overall or cau se- sp ecifi c sunrival between the groups. 
The cl.i.Jucal and pathologic features of the 64 patients u1 the study 
g roup are summarized in Table I . Seven tumors could not b e 
subtyped hi sto logically because th ere was insufficient ti ssu e adja-
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Figure 1. Clinical stage I cutaneous melanomas 4 mnt or greater in 
vertical thickness. Demonstration of proliferating tumor cells by MlB-1. 
immunohistochemical staining of nuclei. n) Melanoma with low MIB-1 
expression (reactivity less than 1 O'Y.•). b) Tumor with high MIB-1 expression 
(reactivity greater than 20%). Bars, 100 J.L111 . 
cent to the tumor to assess whether a radial growth phase was 
present. Patients were followed up for a median of 3.8 years (range 
0.42-13.6 years). Thirty-six of the 64 patients developed recurrent 
disease; of these, 30 died of their disease, one patient is alive with 
disease, three are alive with no evidence of disease, and two were 
lost to follow-up. Of th e 28 patients without recurrences, 20 are 
alive w ith no evidence of disease, six died with no evidence of 
disease, and two were lost to follow-up. Seven patients were 
followed for less than 1 year: one with recurrent disease was lost to 
follow-up and the other six died, five of disease. All of the 13 
patients with follow-up for 1-2 years died of m elanoma. The 
remaining 44 patients have been followed up for at least 2 years and 
of these, 12 died of melanoma and five died of other causes. A 
further three patients were lost to follow-up, one of whom 
developed recurrent melanoma before leaving the clinic. At the 
time of writing, 23 patients were alive with no evidence of disease 
and one patient was alive with disease. 
Tumor nuclei reactive for the MIB-1 antigen were found in both 
the epidermal and dermal compon ents of melanomas, but the 
pattern of immunoreactivity was heterogeneous in different lesions. 
In some melanomas, the reactive nuclei were diffusely distributed 
throughout the tumors, whereas others exhibited focal aggregates 
of immunoreactive nuclei. The MID-1 reactivity scores were as 
follows: low (less than 1 0%) in 33 cases, intermediate (10% to 20%) 
in 17 cases, and high (greater than 20%) in 1.4 cases (Fig 1). T he 
range of MIB-1 positivity was 0% to 44%. Three melanomas 
showed no MID-1 expression despite a reactive intemal control. 
The correlation of vertical depth with either mitotic rate (r = 
0.157, p = 0.2138) or MIB-1 reactivity (r = 0.127, p = 0.3125) was 
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Figure 2. Cause-specific survival curves in patients with clinical 
stage I cutaneous melanomas rneasuring 4 mm or greater based on 
proliferative activity by MIB-1 intmunohistocbemistry. Percentages 
of MIB-1-reactive tumor nuclei were scored as low (less than 1 0%), 
intermediate (10% to 20%), or high (greater than 20%). Comparisons of 
survival curves were significant for low versus high Mlli-1 proliferative rates (p 
< 0.0001) and for intermediate versus high MIB-1 proliferative rates (p "" 
0.0025). There was no significant dilfcrcnce in survival rates between low 
and intermediate MID-1 proliferative rates (p = 0.4957). 
not significant. ln contrast, the correlation between MIB-1 immu-
noreactivity and the mitotic index was highly significant (r = 0.473, 
p < 0.0001). 
There was a lower cause-specific survival rate in those patients 
with melanomas with l1.igh proliferation rates (MIB-1 reactivity 
greater than 20%) than in patients with tumors oflow proliferation 
(MIB-1 reactivity less than 10"1.•) or intennediate proliferation 
(Mlli-1 reactivity 10'Vo to 20%) (Fig 2). The higher survival rate of 
patients with low MIB-1-positive tumors compared with those 
with high M£B-1-reactive melanomas was significant (p < 0.0001) , 
as was the comparison between p<1tients with tumor,s of intermedi-
ate and high Mlli-1 proliferative rates (p = 0.0025). There was no 
significant difference in survival rates between patients with tumors 
of low and intermediate MIB-1 scores (p = 0.4957). A similar 
association was demonstrated between MIB-1 proliferative rates 
and overall survival. 
The results of the Cox regression model for overall survival and 
cause- specific survival are shown in Table II. For overall survival, 
the only variables that attained statistical significance were age ar 
diagnosis (p = 0.0055) and Mffi-1 immw10reactivity (p < 0.0001). 
For cause-specific survival, the only variable that was statistically 
significant was Mill-1 immw10reactivity (p = 0.0002); vertical 
depth approached statistical significance (p == 0.0585). 
DISCUSSION 
Our results show that the proliferation rate determined by MIB-1 
immunohistochemistry is inversely correlated with cause-specific 
and overall survival. Moreover, in the multivariate analysis, Mlli-1 
proliferative activity was the single most significant prognostic 
factor in this group of clinical stage l patients with thick cutaneous 
melanomas. The majority of immunohistochemical studies of pro-
liferation in m elanoma have examined proliferation only with 
respect to other pathologic factors such as vertical thickness 
[11,23,25,26], Clark level of invasion [14], nuclear size (23,24], or 
mitotic rate [25,26]. Those few investigations that examined the 
level of expression of proliferation antigens with reference to 
patient outcome are not comparable to our study in tenns of 
high-risk stage I patients. Furthermore, these studies have several 
limitations. First, proliferation has not been evaluated as an inde-
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Table II. Multivariate Analysis of Prognostic Factors 
With Overall and Cause-Specific Survival in Patients 
With Clinical Stage I Cutaneous Melanoma (Tumor 
Thickness 4 .00 mm or Greater) 
Overall Cause-Specific 
Sun•ival Survival 
Variable (p Value) (p Value) 
Clinical 
Age 0.0055" 0.0797 
Sex 0.9997 0.9896 
Site 0.2726 0.1358 
BANS1' 0.2222 0.3917 
Pathology 
Type 0.3508 0.2724 
Level 0.6881 0.2658 
Thickness 0.0700 0.0585 
Ulceration 0.7661 0.3552 
R.egression 0.6970 0.2627 
Proliferation 
Mlli-1 % < 0.0001 " 0.0002" 
M.ffi pattern 0.2929 0.4170 
Mitotic index 0.3867 0.9123 
a p < 0.05; statistically significant. 
• BANS, upper back, upper posterior ann, posterior neck, scalp region. 
pendent prognostic factor in multivariate analysis of clinical and 
pathologic factors but rather as an attribute in combination with 
other pathologic features such as the vertical thickness measure-
ment [11] or tumor cell motility [12]. Second, immunohistochem-
ical studies based on PCNA [16, 17] or Ki-67 [11, 12] are limited by 
technical considerations [13,18] and a shorter follow-up period 
than in the current study. Because the mitotic index and detection 
of proliferation- associated nuclear antigens both measure prolifer-
ation, is not surprising that there is a correlation between the 
factors. However, in contrast to MID-1 immunoreactivity, the 
mitotic index is not a statistically significant prognostic factor in 
multivariate analysis. The failure of the mitotic index to show 
statistical significance as an independent prognostic attribute in our 
study may reflect the fact that it recognizes only a fraction of the 
cells in the proliferative phase as compared with Mm-1, which 
identifies all proliferating cells from G, to M. 
The presence of focal aggregates ofMID-1-reactive tumor nuclei 
was not significant in our study; other investigators have suggested 
that focal aggregates of PCNA reactivity may reflect tumor heter-
ogeneity or clones more likely to invade or metastasize [14]. 
In this series of thick cutaneous melanomas, the only other 
clinical or pathologic factor in the multivariate analysis that ap-
proached statistical significance was vertical thickness. By restrict-
ing the range of thiclmess of the melanomas studied, we may have 
decreased the variability of tlus factor and thus obscured its true 
value as a prognostic factor. Nonetheless, the results of our study 
identified a potential prognostic attribute in a select group of stage 
I patients whose overall prognosis based on tumor thickness is poor. 
The advantages of studying patients with thick melanomas are that 
their clinical outcome will be apparent within a few years and that 
there is a subgroup of patients with a better prognosis . It would also 
be important to study low-level melanomas to identify those few 
patients with a poor prognosis. Large numbers of cases would be 
required, however, to show statistical significance; the follow-up 
period would have to be longer, and the volume of melanoma 
tissue would not necessarily be adequate to perform such a study. 
As with all retrospective studies, tlus investigation has some 
limitations. First, not all paraffin tissue blocks could be retrieved; 
however, tl1ere was no sig1Uficant difference in survival or in 
clinical and pathologic features between the patients studied and 
those whose tumors were not available for MIB-1 immunolusto-
chenlistry. Second, although the majority of patients were referred 
to the Melanoma Clinic within 5 weeks of diag11osis, some patients 
had later referrals; however, there was no sigtlificant difference in 
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survival between these groups. Therefore, although this study is not 
a complete assessment of all 97 patients and is not a true inception 
cohort among the 64 patients studied, we believe that any possible 
selection bias is small and is unlikely to alter the importance of our 
observations . 
We have demonstrated that MID-1 proliferative activity is an 
independent prognostic factor in melanomas measuring 4 mm or 
greater in tluckness. Thus, a subset of patients can be identified who 
are at lower risk of recurrent disease tl1an is otherwise indicated by 
measurement of the vertical tluckness of their tumors. This knowl-
edge will be important for assessment of new treatment modalities 
for tluck melanomas. 
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